Competing goals of patient vs corporate health means only highly profitable medicines are developed, leaving many needed solutions and possible cures wanting. A void we intend to FYX.
John Hare, FYX Therapeutics.

We have developed and registered the World’s first legitimate treatments using oral antibodies and are confident they can be used to produce better and more sustainable health solutions.

C Diff FYX, now in phase 2 clinical trial as a treatment against C Difficile bacteria infection, will replace antibiotics, with no resistance or side effects.

Positive proof of concept results have also been observed for:

• Obesity
• Traveler’s Diarrhea
• Acid Reflux
• Arthritis
• Asthma
• IBS

Other potential targets include

• IBD
• Covid-19
• UTI
• Stress
• Anxiety
• Depression
• Heart Disease
• Colorectal cancer
• Alzheimer’s
• Parkinson’s
• Autism

We are initially looking for financial assistance to complete phase trials of our C Difficile treatment (C Diff FYX). Please contact John Hare for more information (941-221-2505).